Market
EU announces funding for psychedelic therapy trials by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the European Union
Story
UCL to Trial Dimethyltryptamine (DMT) on UK Volunteers to Combat Alcohol Misuse
Jan 19, 2025, 12:45 PM
Scientists at University College London (UCL) are set to trial the psychedelic drug dimethyltryptamine (DMT) on UK volunteers in an effort to address alcohol misuse. The study aims to determine whether a single dose of this powerful hallucinogen can assist individuals in reducing their alcohol intake. DMT, known for its use in traditional healing ceremonies, has garnered interest as a potential therapeutic agent in treating substance dependence. This initiative aligns with broader discussions in the European Union regarding the regulation and funding of psychedelic therapies, as various organizations advocate for equitable access to such treatments across member states.
View original story
Similar markets
Same level of funding • 25%
Increased funding • 25%
Decreased funding • 25%
No funding • 25%
United Kingdom • 25%
Canada • 25%
United States • 25%
Australia • 25%
Psilocybin • 25%
Other • 25%
Ayahuasca • 25%
LSD • 25%
Effective only for alcohol use disorder • 25%
Not effective for either condition • 25%
Effective for both PTSD and alcohol use disorder • 25%
Effective only for PTSD • 25%
Depression • 25%
Addiction • 25%
PTSD • 25%
Anxiety • 25%
Roche • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
No • 50%
Yes • 50%
